Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Triple-negative breast cancer (TNBC) accounts for 10%-20% of all breast cancers.1 It has high recurrence and metastasis rates and has the worst prognosis among the known breast cancer subtypes.2 There are no clear treatment targets for this cancer, and the treatment options are limited. Currently, neoadjuvant therapy is the standard treatment for patients with early-stage TNBC who have lymph node-positive tumors or tumors that are >2 cm in size.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
